The Patent Finder

Genome and Company

9 patents currently held · Updated Nov 21, 2026
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Jan 2039
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Apr 17, 2027
    The maintenance fee for Pharmaceutical composition for preventing or treating cancer comprising LRIT2 inhibitor as active ingredient (US 11,787,870) comes due Apr 17, 2027. Unpaid by Oct 18, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 of the patents on this record was granted since Aug 23, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 9 of 9

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 11,571,448Lactobacillus rhamnosus LM1019 strain and composition for preventing and treating obesity or diabetes mellitus comprising same
In force
 · USPTO record
In forceUSPTO record
US 11,406,589Cutibacterium granulosum strain, and composition comprising such strain or culture thereof for preventing or treating acne
In force
 · USPTO record
In forceUSPTO record
US 11,478,513Cutibacterium avidum strain, and composition for preventing or treating atopic dermatitis, comprising strain or cultured product thereof
In force
 · USPTO record
In forceUSPTO record
US 11,453,857Lactobacillus fermentum LM1016 strain (KCCM12468P)
In force
 · USPTO record
In forceUSPTO record
US 11,787,870Pharmaceutical composition for preventing or treating cancer comprising LRIT2 inhibitor as active ingredient
In force
 · USPTO record
In forceUSPTO record
US 12,214,004Strains having effects of preventing or treating cancers
In force
 · USPTO record
In forceUSPTO record
US 12,790,393ANTI-CNTN4-SPECIFIC Antibodies and Use Thereof
In force
 · High confidence
In forceHigh confidence
US 12,600,765Novel Target for Anti-Cancer and Immune-Enhancing
In force
 · Low confidence
In forceLow confidence
US 12,564,613Novel Strains Having Effects of Preventing or Treating Cancers
In force
 · High confidence
In forceHigh confidence
Also on record, not counted in the 9: 1 patent in force now held by others. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

4 pending · 3 abandoned · 8 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited